These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity. Nakajima N; Nobusawa S; Nakata S; Nakada M; Yamazaki T; Matsumura N; Harada K; Matsuda H; Funata N; Nagai S; Nakamura H; Sasaki A; Akimoto J; Hirato J; Yokoo H Brain Pathol; 2018 Sep; 28(5):663-673. PubMed ID: 29105198 [TBL] [Abstract][Full Text] [Related]
3. A case of an epithelioid glioblastoma with the BRAF V600E mutation colocalized with BRAF intact low-grade diffuse astrocytoma. Kuroda J; Nobusawa S; Nakamura H; Yokoo H; Ueda R; Makino K; Yano S; Kuratsu J Neuropathology; 2016 Apr; 36(2):181-6. PubMed ID: 26375727 [TBL] [Abstract][Full Text] [Related]
4. A case of osteoclast-like giant cell-rich epithelioid glioblastoma with BRAF V600E mutation. Funata N; Nobusawa S; Yamada R; Shinoura N Brain Tumor Pathol; 2016 Jan; 33(1):57-62. PubMed ID: 26602910 [TBL] [Abstract][Full Text] [Related]
5. Epithelioid glioblastoma arising from pleomorphic xanthoastrocytoma with the BRAF V600E mutation. Tanaka S; Nakada M; Nobusawa S; Suzuki SO; Sabit H; Miyashita K; Hayashi Y Brain Tumor Pathol; 2014 Jul; 31(3):172-6. PubMed ID: 24894018 [TBL] [Abstract][Full Text] [Related]
6. Clinicopathological and genetic association between epithelioid glioblastoma and pleomorphic xanthoastrocytoma. Furuta T; Miyoshi H; Komaki S; Arakawa F; Morioka M; Ohshima K; Nakada M; Sugita Y Neuropathology; 2018 Jun; 38(3):218-227. PubMed ID: 29532523 [TBL] [Abstract][Full Text] [Related]
7. Adult classical glioblastoma with a BRAF V600E mutation. Takahashi Y; Akahane T; Sawada T; Ikeda H; Tempaku A; Yamauchi S; Nishihara H; Tanaka S; Nitta K; Ide W; Hashimoto I; Kamada H World J Surg Oncol; 2015 Mar; 13():100. PubMed ID: 25885250 [TBL] [Abstract][Full Text] [Related]
8. Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy. Kanemaru Y; Natsumeda M; Okada M; Saito R; Kobayashi D; Eda T; Watanabe J; Saito S; Tsukamoto Y; Oishi M; Saito H; Nagahashi M; Sasaki T; Hashizume R; Aoyama H; Wakai T; Kakita A; Fujii Y Acta Neuropathol Commun; 2019 Jul; 7(1):119. PubMed ID: 31345255 [TBL] [Abstract][Full Text] [Related]
9. Clinicopathological characteristics of circumscribed high-grade astrocytomas with an unusual combination of BRAF V600E, ATRX, and CDKN2A/B alternations. Murakami C; Yoshida Y; Yamazaki T; Yamazaki A; Nakata S; Hokama Y; Ishiuchi S; Akimoto J; Shishido-Hara Y; Yoshimoto Y; Matsumura N; Nobusawa S; Ikota H; Yokoo H Brain Tumor Pathol; 2019 Jul; 36(3):103-111. PubMed ID: 30972500 [TBL] [Abstract][Full Text] [Related]
10. Malignant transformation of diffuse astrocytoma to glioblastoma associated with newly developed BRAF V600E mutation. Kanamori M; Suzuki H; Takei H; Sonoda Y; Uenohara H; Tominaga T Brain Tumor Pathol; 2016 Jan; 33(1):50-6. PubMed ID: 26404554 [TBL] [Abstract][Full Text] [Related]
11. BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation. Kleinschmidt-DeMasters BK; Aisner DL; Foreman NK Am J Surg Pathol; 2015 Apr; 39(4):528-40. PubMed ID: 25581727 [TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical and molecular genetic study on epithelioid glioblastoma: Series of seven cases with review of literature. Khanna G; Pathak P; Suri V; Sharma MC; Chaturvedi S; Ahuja A; Bhardwaj M; Garg A; Sarkar C; Sharma R Pathol Res Pract; 2018 May; 214(5):679-685. PubMed ID: 29615337 [TBL] [Abstract][Full Text] [Related]
13. Glioblastoma in neurofibromatosis 1 patients without IDH1, BRAF V600E, and TERT promoter mutations. Shibahara I; Sonoda Y; Suzuki H; Mayama A; Kanamori M; Saito R; Suzuki Y; Mashiyama S; Uenohara H; Watanabe M; Kumabe T; Tominaga T Brain Tumor Pathol; 2018 Jan; 35(1):10-18. PubMed ID: 29138945 [TBL] [Abstract][Full Text] [Related]
14. Epithelioid glioblastoma with microglia features: potential for novel therapy. Nakagomi N; Sakamoto D; Hirose T; Takagi T; Murase M; Nakagomi T; Yoshimura S; Hirota S Brain Pathol; 2020 Nov; 30(6):1119-1133. PubMed ID: 32687679 [TBL] [Abstract][Full Text] [Related]
15. Cerebellar glioblastoma: a clinical series with contemporary molecular analysis. Hong B; Banan R; Christians A; Nakamura M; Lalk M; Lehmann U; Hartmann C; Krauss JK Acta Neurochir (Wien); 2018 Nov; 160(11):2237-2248. PubMed ID: 30203362 [TBL] [Abstract][Full Text] [Related]
16. Glioblastoma in a female neurofibromatosis 1 patient without IDH1, BRAF V600E, and TERT promoter mutations: A case report. Cai JW; Chen XY; Chen JY; Wu ZY; Wu XY; Yu LH; You HH Medicine (Baltimore); 2021 Apr; 100(13):e25346. PubMed ID: 33787635 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of EZH2 expression, BRAF V600E mutation, and CDKN2A/B deletions in epithelioid glioblastoma and anaplastic pleomorphic xanthoastrocytoma. Wang J; Liu Z; Cui Y; Liu Y; Fang J; Xu L; He Y; Du J; Su Y; Zou W; Xu Z; Li G J Neurooncol; 2019 Aug; 144(1):137-146. PubMed ID: 31214915 [TBL] [Abstract][Full Text] [Related]
18. Additional genetic alterations in BRAF-mutant gliomas correlate with histologic diagnoses. Dono A; Vu J; Anapolsky M; Hines G; Takayasu T; Yan Y; Tandon N; Zhu JJ; Bhattacharjee MB; Esquenazi Y; Ballester LY J Neurooncol; 2020 Sep; 149(3):463-472. PubMed ID: 33009979 [TBL] [Abstract][Full Text] [Related]